Insider Selling: Bio-Rad Laboratories (NYSE:BIO) EVP Sells $214,326.00 in Stock

Bio-Rad Laboratories, Inc. (NYSE:BIO) EVP James Barry sold 700 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $306.18, for a total transaction of $214,326.00. Following the sale, the executive vice president owned 510 shares in the company, valued at $156,151.80. The trade was a 57.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Bio-Rad Laboratories Stock Up 4.6%

BIO opened at $327.62 on Thursday. Bio-Rad Laboratories, Inc. has a 12 month low of $211.43 and a 12 month high of $373.69. The company has a market cap of $8.87 billion, a PE ratio of -13.48 and a beta of 1.04. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17. The company has a 50 day moving average of $301.44 and a 200 day moving average of $269.06.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Wednesday, October 29th. The medical research company reported $2.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.30 by ($0.04). Bio-Rad Laboratories had a positive return on equity of 4.18% and a negative net margin of 26.43%.The company had revenue of $653.00 million for the quarter, compared to analysts’ expectations of $651.30 million. During the same quarter in the prior year, the company earned $2.01 EPS. The company’s revenue was up .5% on a year-over-year basis. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Institutional Investors Weigh In On Bio-Rad Laboratories

Hedge funds have recently bought and sold shares of the stock. Principal Financial Group Inc. lifted its stake in Bio-Rad Laboratories by 0.5% in the first quarter. Principal Financial Group Inc. now owns 44,343 shares of the medical research company’s stock worth $10,800,000 after purchasing an additional 236 shares during the last quarter. Crossmark Global Holdings Inc. grew its stake in shares of Bio-Rad Laboratories by 14.6% during the first quarter. Crossmark Global Holdings Inc. now owns 966 shares of the medical research company’s stock valued at $235,000 after buying an additional 123 shares during the last quarter. Amundi increased its holdings in shares of Bio-Rad Laboratories by 16.4% in the first quarter. Amundi now owns 23,336 shares of the medical research company’s stock worth $5,478,000 after buying an additional 3,294 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in shares of Bio-Rad Laboratories in the 1st quarter valued at about $816,000. Finally, Acadian Asset Management LLC boosted its holdings in Bio-Rad Laboratories by 79.6% during the 1st quarter. Acadian Asset Management LLC now owns 73,431 shares of the medical research company’s stock valued at $17,878,000 after acquiring an additional 32,534 shares during the period. 65.24% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on BIO. Zacks Research upgraded Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Weiss Ratings upgraded shares of Bio-Rad Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, October 30th. Royal Bank Of Canada upped their target price on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an “outperform” rating in a report on Friday, August 1st. Wells Fargo & Company raised their price target on shares of Bio-Rad Laboratories from $265.00 to $340.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. Finally, Citigroup upped their price target on shares of Bio-Rad Laboratories from $350.00 to $375.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $358.50.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.